Physician profile
Thomas C Lee
NPI 1568652261
$17,387.62
in general payments reported to CMS, 2019-2025
36 companies · $3,198 in 2025
The $3,198 reported for 2025 was more than what 87% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,821 · 2020: $669 · 2021: $2,140 · 2022: $2,574 · 2023: $2,540 · 2024: $3,446 · 2025: $3,198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,157 · Education: $26.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,156.75 |
| Education | $26.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,879.53 | 2019-2025 | |
| Janssen Biotech, INC. | $2,067.33 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,531.27 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,393.61 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Covidien LP | $1,058.33 | 2019 | |
| Pfizer INC. | $917.40 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $524.15 | 2022-2025 | Dupixent |
| Braintree Laboratories, INC. | $440.74 | 2019-2024 | Sutab, Suflave |
| Gilead Sciences, INC. | $437.98 | 2020-2025 | Livdelzi |
| Qol Medical, LLC | $429.69 | 2019-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $421.31 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $379.12 | 2022-2025 | Ocaliva |
| Celgene Corporation | $303.31 | 2021-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $301.25 | 2019-2024 | Rebyota, Clenpiq |
| Merck Sharp & Dohme LLC | $284.53 | 2019-2025 | Dificid, Bridion |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $248.00 | 2019-2024 | Linzess |
| Lilly USA, LLC | $238.72 | 2024-2025 | Omvoh |
| Aimmune Therapeutics, INC. | $217.54 | 2024-2025 | Vowst |
| Ipsen Biopharmaceuticals, INC | $181.79 | 2024-2025 | Iqirvo |
| Genzyme Corporation | $131.45 | 2024-2025 | |
| Ardelyx, INC. | $129.42 | 2022-2025 | Ibsrela |
| Penumbra, INC. | $127.25 | 2023 | Indigo System |
| Phathom Pharmaceuticals, INC. | $114.77 | 2024-2025 | Voquezna |
| Allergan, INC. | $112.64 | 2019 | |
| Celltrion USA INC. | $94.25 | 2024-2025 | Vegzelma, Zymfentra, Yuflyma |
| Ucb, INC. | $87.53 | 2019 | |
| Exact Sciences Corporation | $81.30 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $76.55 | 2022-2023 | Amjevita, Avsola |
| Nestle Healthcare Nutrition INC. | $45.85 | 2021-2023 | |
| Fresenius Kabi USA, LLC | $34.72 | 2023 | Idacio |
| Mallinckrodt Hospital Products INC. | $21.81 | 2023 | Terlivaz |
| Shire North American Group INC | $18.95 | 2019 | |
| Alnylam Pharmaceuticals INC. | $15.00 | 2023 | Givlaari |
| Organon LLC | $13.93 | 2024 | |
| Boston Scientific Corporation | $13.32 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.28 | 2023 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.